Prognostic importance of VEGF-A haplotype combinations in a stage II colon cancer population

Pharmacogenomics

Volumn 13, Issue 7, 2012, Pages 763-770

  Kjaer Frifeldt, Sanne ^a,b   Fredslund, Rikke ^a   Lindebjerg, Jan ^a   Hansen, Torben Froestrup ^a   Spindler, Karen Lise Garm ^a,b   Jakobsen, Anders ^a,b  

^a LILLEBAELT HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Colon cancer; Haplotypes; Prognostic marker; SNPs; VEGF A

Indexed keywords

DNA; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER TISSUE; COHORT ANALYSIS; COLON CANCER; COLON SURGERY; DENMARK; DISEASE FREE SURVIVAL; DNA EXTRACTION; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR DIFFERENTIATION; VEGF A GENE;

ADULT; AGED; AGED, 80 AND OVER; COLONIC NEOPLASMS; DENMARK; FEMALE; GENOTYPE; HAPLOTYPES; HOMOZYGOTE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84861120112     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.38     Document Type: Article

References (23)

1. Kopetz S, Freitas D, Calabrich AF, Hoff PM. Adjuvant chemotherapy for stage II colon cancer. Oncology (Williston Park) 22(3), 260-270 (2008).
2. Benson AB 3rd, Schrag D, Somerfield MR et al. American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J. Clin. Oncol. 22(16), 3408-3419 (2004). (Pubitemid 41103700)
3. Figueredo A, Coombes ME, Mukherjee S. Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst. Rev. (3), CD005390 (2008).
4. Andre T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 27(19), 3109-3116 (2009).
5. Lombardi L, Morelli F, Cinieri S et al. Adjuvant colon cancer chemotherapy: where we are and where we'll go. Cancer Treat. Rev. 36(Suppl. 3), S34-S41 (2010).
6. Gangadhar T, Schilsky RL. Molecular markers to individualize adjuvant therapy for colon cancer. Nat. Rev. Clin. Oncol. 7(6), 318-325 (2010).
7. Bastos DA, Ribeiro SC, de Freitas D, Hoff PM. Combination therapy in high-risk stage II or stage III colon cancer: current practice and future prospects. Ther. Adv. Med. Oncol. 2(4), 261-272 (2010).
8. Marsoni S. Efficacy of adjuvant fluorouracil and leucovorin in stage B2 and C colon cancer. International multicenter pooled analysis of colon cancer trials investigators. Semin. Oncol. 28(1 Suppl. 1), 14-19 (2001).
9. Mamounas E, Wieand S, Wolmark N et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four national surgical adjuvant breast and bowel project adjuvant studies (C-01, C-02, C-03 and C-04). J. Clin. Oncol. 17(5), 1349-1355 (1999). (Pubitemid 29220839)
10. O'Connor ES, Greenblatt DY, Loconte NK et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J. Clin. Oncol. 29(25), 3381-3388 (2011).
11. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 100(1), 57-70 (2000). (Pubitemid 30046295)
12. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12(8), 1232-1235 (2000). (Pubitemid 30611801)
13. Lu H, Shu XO, Cui Y et al. Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res. 65(12), 5015-5019 (2005). (Pubitemid 40827307)
14. Maltese P, Canestrari E, Ruzzo A et al. VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population. Int. J. Colorectal Dis. 24(2), 165-170 (2009).
15. Smerdel MP, Waldstrom M, Brandslund I, Steffensen KD, Andersen RF, Jakobsen A. Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer. Int. J. Gynecol. Cancer 19(4), 578-584 (2009).
16. Kim JG, Chae YS, Sohn SK et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin. Cancer Res. 14(1), 62-66 (2008).
17. Hansen TF. The prognostic value of haplotypes in the vascular endothelial growth factor A gene in colorectal cancer. Cancers 2(3), 1405-1418 (2010).
18. Dassoulas K, Gazouli M, Rizos S et al. Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol. Carcinog. 48(6), 563-569 (2009).
19. Stephens M, Scheet P. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am. J. Hum. Genet. 76(3), 449-462 (2005). (Pubitemid 40250525)
20. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68(4), 978-989 (2001). (Pubitemid 32289743)
21. Hansen TF, Spindler KL, Lorentzen KA et al. The importance of-460 C/T and +405 G/C single nucleotide polymorphisms to the function of vascular endothelial growth factor A in colorectal cancer. J. Cancer Res. Clin. Oncol. 136(5), 751-758 (2010).
22. Cacev T, Loncar B, Seiwerth S, Spaventi S, Kapitanovic S. Vascular endothelial growth factor polymorphisms-1154 G/A and-460 C/T are not associated with VEGF mRNA expression and susceptibility to sporadic colon cancer. DNA Cell Biol. 27(10), 569-574 (2008).
23. Jain L, Vargo CA, Danesi R et al. The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol. Cancer Ther. 8(9), 2496-2508 (2009).